LIXTE Biotechnology Holdings, Inc. has expanded its innovative clinical trial for ovarian clear cell cancer treatment by adding the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as its second study site. The trial, which combines LIXTE's proprietary compound LB-100 with GSK's immunotherapy drug dostarlimab, has already begun patient recruitment with the first participant receiving treatment at the new location.
Dr. Emily M. Hinchcliff, MD, MPH, will spearhead the clinical investigation at the Lurie Cancer Center, a prestigious National Cancer Institute-designated Comprehensive Cancer Center based at Northwestern Memorial Hospital's downtown Chicago campus. The expansion follows the trial's initial launch in January 2024 at The University of Texas MD Anderson Cancer Center, where Dr. Amir Jazaeri, Professor of Gynecologic Oncology, serves as the lead clinical investigator.
Novel Therapeutic Approach
The study explores an innovative treatment strategy in the field of activation lethality, combining LIXTE's first-in-class PP2A inhibitor LB-100 with immunotherapy. Previous research has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity, suggesting potential for improving outcomes when used alongside various chemotherapies or immunotherapies.
"Clinical trials testing potentially effective therapies are essential to move our field forward, with many recent great successes," stated Dr. Hinchcliff. "We are pleased to be participating in this important clinical trial to assess whether adding LIXTE's LB-100 to GSK's Dostarlimab will enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma, a disease of high unmet need."
Strategic Expansion
Bas van der Baan, LIXTE's Chief Executive Officer, emphasized the strategic importance of adding the Lurie Cancer Center as a study site. "The addition of Lurie Cancer Center is a positive step in expanding the patient population and accelerating this clinical trial," he noted. This expansion reflects LIXTE's commitment to advancing novel cancer treatments through its comprehensive patent-protected portfolio.
The trial represents a pioneering effort in cancer biology, as LIXTE's approach has no known competitors in the field. The company's focus on PP2A inhibition through LB-100 represents a new treatment paradigm in oncology, particularly for challenging conditions like ovarian clear cell cancer where current therapeutic options are limited.
